Trial Profile
HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia
- Focus Adverse reactions
- Acronyms FASTER
- 06 Aug 2020 Status changed from active, no longer recruiting to completed.
- 12 Apr 2017 New trial record